Xencor, Inc.
Sep 20, 2017
PDF

Xencor to Present at Upcoming Investor Conferences

MONROVIA, Calif., Sept. 20, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will present a corporate update at two upcoming conferences:

  • Cantor Fitzgerald Global Healthcare Conference
    Date: Wednesday, September 27, 2017
    Time: 1:40 p.m. ET
    Location: New York, NY

  • Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
    Date: Thursday, September 28, 2017
    Time: 8:30 a.m. ET
    Location: New York, NY

Xencor, Inc. Logo

Live webcasts of both events will be available on the "Events & Presentations" section in the Investors section of the Company's website located at http://investors.xencor.com/events.cfm. A replay of the presentations will be posted on the Xencor website approximately one hour after the live events and will be available for 30 days following the presentations.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, 11 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internal programs include: XmAb®5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb®7195 in Phase 1 development for the treatment of asthma and allergic diseases; XmAb®14045 in Phase 1 development for acute myeloid leukemia; XmAb®13676 in Phase 1 development for B-cell malignancies; XmAb®18087 in pre-clinical development for the treatment of neuroendocrine tumors; and XmAb®20717 in pre-clinical development for the treatment of multiple cancers. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action.  Xencor partners include Novartis, Amgen, MorphoSys, Merck, CSL/Janssen, Alexion and Boehringer Ingelheim. For more information, please visit www.xencor.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/xencor-to-present-at-upcoming-investor-conferences-300521475.html

SOURCE Xencor, Inc.

News Provided by Acquire Media